UPS - LEIDER IST IHR BROWSER VERALTET!

Um zukunftsfähig zu sein, wurde unsere aktuelle Webseite für die neuesten Technologien entwickelt.
Daher können bei alten Browsern leider Probleme auftreten.
Damit die neue Börse-Online-Seite richtig funktioniert und Spaß macht, empfehlen wir Ihnen einen dieser aktuellen und kostenlosen Browser herunterzuladen:

Achieve Life Sciences nach Reverse Split

Seite 1 von 25
neuester Beitrag: 16.05.19 15:50
eröffnet am: 25.05.18 17:22 von: bozkurt7 Anzahl Beiträge: 612
neuester Beitrag: 16.05.19 15:50 von: Dölauer Leser gesamt: 51654
davon Heute: 104
bewertet mit 3 Sternen

Seite: Zurück 1 | 2 | 3 | 4 |
23 | 24 | 25 | 25  Weiter  

4375 Postings, 1517 Tage bozkurt7Achieve Life Sciences nach Reverse Split

 
  
    
3
25.05.18 17:22
Ab heute 25.05.2018 gilt die neue WKN A2JMW8.
Wollen wir mal hoffen, dass jetzt endlich die Wende eingeleitet wird.  
Seite: Zurück 1 | 2 | 3 | 4 |
23 | 24 | 25 | 25  Weiter  
586 Postings ausgeblendet.

40 Postings, 696 Tage Dagobert_0815...heute bereits knapp 8% +

 
  
    
05.04.19 16:35
Montag nach der Präsentation kommt der Nachschlag...
m.M.  

1058 Postings, 3244 Tage AdvamillionärDas riecht hier...

 
  
    
05.04.19 19:37
...ganz gewaltig nach einem neuerlichen Ausbruch nach oben.

Gruß vom
Advamillionär  

40 Postings, 696 Tage Dagobert_0815Läuft...

 
  
    
22.04.19 20:53
Wieder 8% plus, der Goldesel funktioniert weiterhin. Kurzfristig wird die 4 $ Marke geknackt. Wie immer meine Meinung





 

4129 Postings, 5178 Tage martin30smNews

 
  
    
24.04.19 13:27
Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation
Topline data from ORCA-1 trial expected in the Second Quarter of 2019
SEATTLE and VANCOUVER, British Columbia, April 24, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that the last study visit for the last subject enrolled in the ORCA-1 trial occurred on April 23, 2019. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter.

ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, which aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other addiction indications. ORCA-1 was initiated in October 2018 and enrolled 254 smokers at eight centers across the United States. Importantly, the trial's Data Safety Monitoring Committee met recently to conduct its final safety review and concluded there are no safety concerns for subjects or study conduct issues, and the trial should continue for completion.

Dr. Cindy Jacobs, Chief Medical Officer at Achieve commented, "Completing this trial represents a significant milestone in the cytisinicline development program and we continue to be impressed by the efficient conduct of our investigators and the commitment of the subjects who, like millions of people, are combatting nicotine addiction."

Additional information on cytisinicline and the ORCA program can be found at www.achievelifesciences.com and www.orcaprogram.com.

About Cytisinicline
Tobacco use is currently the leading cause of preventable death and is responsible for nearly seven million deaths annually worldwide1. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking2. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

About ORCA-1
The Phase 2b ORCA-1 trial is evaluating a 25-day treatment course of 1.5 mg or 3.0 mg doses of cytisinicline using either a declining titration schedule or three times daily dosing. The trial is randomized and blinded to compare the effectiveness of the cytisinicline doses and schedules to respective placebo groups. The primary efficacy endpoint is the overall reduction in the number of cigarettes smoked during the treatment period, with secondary analyses being conducted on smoking cessation rates, safety, and compliance. Smokers who are participating in the trial receive standardized behavioral support.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the planned cytisinicline clinical development activities, the timing of clinical development activities related to cytisinicline, the potential market size for cytisinicline and the potential benefits of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4

"ORCA is a trademark of Achieve Life Sciences, Inc."

1World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2Annals of Epidemiology , Volume 25 , Issue 3 , 179 - 182.e1

SOURCE Achieve Life Sciences, Inc.  

2844 Postings, 2679 Tage brauchmehrkohleHier gibt es nur noch eine Richtung

 
  
    
1
24.04.19 13:33
Die Bewertung ist in meinen Augen Anpassungsfähig  

598 Postings, 928 Tage bjkrugim pre schon 10%

 
  
    
24.04.19 13:35
achso, nur noch 6?... :-)  

4129 Postings, 5178 Tage martin30sm...bis 10 Euro :-)

 
  
    
24.04.19 13:47

40 Postings, 696 Tage Dagobert_0815M.E. sind die News bereits seit

 
  
    
24.04.19 14:57
gestern durch die US Amerikaner eingepreist, ich erwarte kurzfristig keine signifikanten Steigerungen.
Long natürlich weiterhin der Knaller.
Wie immer m.M.  

2844 Postings, 2679 Tage brauchmehrkohlevolumen steigt!

 
  
    
24.04.19 17:45
wann wohl der Deckel fliegt 10.... 20... Euro.... Übernahme?? die Bewertung ist ein Witz und ich glaube es geben nicht viele ihre Aktien her. Tenbaggeralarm  

1058 Postings, 3244 Tage AdvamillionärDas hier schreit förmlich...

 
  
    
26.04.19 20:52
...nach einem Ausbruch nach oben!

Gruß vom
Advamillionär  

2844 Postings, 2679 Tage brauchmehrkohleDer schrei wird lauter

 
  
    
29.04.19 10:36
Es gibt nur so wenig Aktien und die meisten werden wohl behalten bei der mk. Für mich völlig unterbewertet könnte sich locker verzehnfachen  

55 Postings, 348 Tage Neonblack667und ich bin auch endlich im Plus

 
  
    
1
29.04.19 13:46
Hab mir zwar geschworen, dass ich, wenn das dass nächste mal der Fall sein wird, verkaufe und nach dem üblichen Crash wieder unten einsteige aber ich glaube fast, dass es diesmal keinen massiven Rücksetzer mehr gibt...  

1058 Postings, 3244 Tage AdvamillionärWohl nur dann, wenn...

 
  
    
29.04.19 18:54
...es nochmal richtig hochschießen sollte (wovon ich bald ausgehe), also mehr als 50 % Tagesgewinn. Dann wird es sicherlich wieder die üblichen Gewinnmitnahmen geben. Aber derzeit geht es langsam und kontinuierlich bergauf, die Gefahr eines größeren Rücksetzers stufe ich daher aktuell als sehr niedrig ein.

Gruß vom
Advamillionär  

40 Postings, 696 Tage Dagobert_0815Quartalsbericht am 15. Mai

 
  
    
1
07.05.19 15:41
Für das 1. Quartal 2019 gibt es am 15.Mai einen m.E. sehr positiven Bericht.
D.h. Achieve wird bis dahin noch einen Satz nach oben machen.
Diese Aktie macht doch in diesem Jahr richtig Spaß, auch zukünftig erwarte ich hier noch einiges.
Wie immer m.M.  

40 Postings, 696 Tage Dagobert_0815...unser Freund aus den USA

 
  
    
13.05.19 16:09
bringt zur Zeit alle Kurse gen Süden....  

572 Postings, 889 Tage DölauerQuartalsbericht

 
  
    
15.05.19 20:57

40 Postings, 696 Tage Dagobert_0815..erst 4:30 pm eastern time,

 
  
    
15.05.19 21:48
noch knapp 45 Minuten dann gibt es den Bericht via webcast  

91 Postings, 513 Tage Siggi JacksonWird wohl bald ne ke kommen

 
  
    
15.05.19 22:15
Nur noch 9,7 Mille Stand 31.3  

4129 Postings, 5178 Tage martin30smZahlen

 
  
    
15.05.19 22:32
Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update

   AddThis Sharing Buttons
   Share to Facebook

Share to TwitterShare to LinkedInShare to Pinterest

SEATTLE and VANCOUVER, British Columbia, May 15, 2019 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today provided an update on the cytisinicline clinical development program and announced first quarter 2019 financial results.

ORCA-1 Trial Status
Achieve's 254-subject Phase 2b ORCA-1 trial of cytisinicline in U.S. smokers completed enrollment in February. The Company announced recently that the last study visit for the last subject enrolled in the ORCA-1 trial has occurred. The trial is evaluating cytisinicline in both the 1.5 mg and 3.0 mg doses on a declining titration schedule as well as three times daily dosing, both over 25 days. The primary efficacy endpoint is reduction in the number of cigarettes smoked during treatment with secondary analyses to be conducted on smoking cessation rates, safety, and compliance. ORCA-1 topline efficacy and safety data are expected to be announced by the end of the second quarter.

Maximum Tolerated Dose (MTD) Trial Extension
Achieve recently initiated a trial to assess the MTD for a single administered oral dose of cytisinicline in smokers. The starting dosage of cytisinicline was 6 mg and is increased in separate groups of subjects for each escalated dose level until stopping criteria, based on the occurrence of dose-limiting adverse events, are reached. To date, 21 mg cytisinicline has been evaluated without evidence of dose limiting toxicity. The trial's Data Safety Monitoring Committee has recommended a protocol amendment to evaluate additional higher doses of cytisinicline.

Rick Stewart, Chairman and Chief Executive Officer of Achieve Life Sciences commented, "With the results of the ORCA-1 trial expected by the end of the second quarter, we are rapidly approaching another critical milestone for the cytisinicline development program. Importantly, as confirmed by the tolerability of high dose levels in our MTD study, we believe cytisinicline may offer a differentiated and new treatment option for the millions of people who are battling nicotine addiction."

Financial Results
As of March 31, 2019, the company's cash, cash equivalents, short-term investments and restricted cash were $9.7 million. Each of total operating expenses and net loss for the first quarter of 2019 were $5.9 million.

As of May 15, 2019 Achieve had 6,865,950 shares outstanding.

Conference Call Details
Achieve will host a conference call at 4:30 p.m. Eastern time today, Wednesday, May 15, 2019. To access the webcast, log on to the investor relations page of the Achieve website at http://ir.achievelifesciences.com/events-and-webcasts. Alternatively, access to the live conference call is available by dialing (877) 472-9809 (U.S. & Canada) or (629) 228-0791 (International) and referencing conference ID 6973659. A webcast replay will be available approximately two hours after the call and will be archived on the website for 90 days.

About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death and is responsible for nearly seven million deaths annually worldwide1. It is estimated that 28.7% of cancer deaths in the U.S. are attributable to cigarette smoking2. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the planned cytisinicline clinical development activities, the timing of clinical development activities related to cytisinicline, expectations from current data, expectations regarding when trial data may be reported, the potential market size for cytisinicline and the potential benefits of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.

Achieve Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4

"ORCA is a trademark of Achieve Life Sciences, Inc."

1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2017. Geneva: World Health Organization, 2017
2 Annals of Epidemiology , Volume 25 , Issue 3 , 179 - 182.e1

Consolidated Statements of Loss

(In thousands, except per share and share data)


                    
                     
                     
                     
                     
           
§
                    
                     
                     
                     
                     
           
§
                    
                     
                     
           
§
 

55 Postings, 348 Tage Neonblack667OK, und das heisst...

 
  
    
15.05.19 22:53
Noch könnte ich bei L&S verkaufen :D  

55 Postings, 348 Tage Neonblack667.

 
  
    
15.05.19 23:16
0.25$ unter den Erwartungen und gerade als ich noch für 3.78? verkaufen wollte, fällt der Kurs...

Mal gespannt wie es weiter geht.  

572 Postings, 889 Tage DölauerEröffnungskurs heute in den USA

 
  
    
16.05.19 15:22
Na wer stellt eine Prognose?
Auch zum Schlusskurs!  

4129 Postings, 5178 Tage martin30smMein Tipp für heute:

 
  
    
1
16.05.19 15:26
Eröffnung bei ca. 4 Dollar, dann kurz runter bis 3,70 Dollar... SK bei ca. 4,40 Dollar  

4129 Postings, 5178 Tage martin30sm@Dölauer: Wie lautet dein Tipp?

 
  
    
16.05.19 15:32

572 Postings, 889 Tage DölauerTipp

 
  
    
1
16.05.19 15:50
Schwer zu sagen, ich denke der Kurs bleibt über 4 Dollar bei wenigen Umsätzen und wird erst steigen, wenn Ende des zweiten Quartals die angekündigten News kommen.    

Seite: Zurück 1 | 2 | 3 | 4 |
23 | 24 | 25 | 25  Weiter  
   Antwort einfügen - nach oben